|
|
|
|
|
|
|
|
"...Thus, although the study by Kaye et al11 does not show a clear advantage of olaparib compared with PLD, it is noteworthy for what it teaches us about the difficulties in performing and interpreting the results of randomized trials that involve this promising class of new agents in patients with recurrent EOC."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.